Pharmaceutical

Merck and AstraZeneca receive approval for Lynparza in Japan

Merck (MSD) and AstraZeneca have received approval in Japan for Lynparza to treat BRCA-mutated (BRCAm) castration-resistant prostate cancer.

Aug 26, 2023 - 20:00
Merck and AstraZeneca receive approval for Lynparza in Japan
Merck (MSD) and AstraZeneca have received approval in Japan for Lynparza to treat BRCA-mutated (BRCAm) castration-resistant prostate cancer.
Read the original article

Tags:

Previous Article

Five ways to build trust in patient data sharing

Next Article

FDA Panel’s Divided Verdict Delays Approval for Medtronic’s Blood Pressure Device

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA backs Astellas-Pfizer’s Padcev with Keytruda for urothelial cancer

FDA backs Astellas-Pfizer’s Padcev with Keytruda for ur...

Dec 18, 2023

EpiBiologics names Ann Lee-Karlon as CEO and president

EpiBiologics names Ann Lee-Karlon as CEO and president

Jul 21, 2023

Sudo secures additional funds to advance TYK2 inhibitors to clinic

Sudo secures additional funds to advance TYK2 inhibitor...

Feb 14, 2024